Why the study?
Do oral anticoagulants like dabigatran or rivaroxaban increase the risk of gastrointestinal bleeding compared to warfarin in commercially insured adults?
Do oral anticoagulants like dabigatran or rivaroxaban increase the risk of gastrointestinal bleeding compared to warfarin in commercially insured adults?
In a commercially insured US cohort, while overall GI bleeding rates appeared similar, clinically significant increases in bleeding risk with dabigatran or rivaroxaban compared to warfarin could not be excluded.
Cannot exclude up to 50% or >2-fold higher GI bleeding risk with dabigatran or rivaroxaban; leaves open comparative safety versus warfarin.
Although rates of gastrointestinal bleeding seem to be similar in this commercially insured sample of adults in the United States, we cannot rule out as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: